Table 3. Prognostic impact of response level in patients with relapsed or refractory multiple myeloma.
| Reference Response criteria Study type Patients | Treatment | Response | n | PFS/TTP/EFS (median, moa/rate, %) | OS (median, moa/rate, %) | ||||
|---|---|---|---|---|---|---|---|---|---|
| mTTP | P-value | mOS | P-value | ||||||
| Niesvizky et al.66 mEBMT Ph 3 post hoc Relapsed | BTZ arm | CR VGPR PR MR non-response | 27 31 77 21 159 | 9.7 10.8 8.5 4.9 2.8 | — | 0.016 MR versus non-response | NR NR NR 24.9 18.7 | — | — |
| EFS | 1 yr | P-value | OS | 1 yr | P-value | ||||
| Palumbo et al.67 IMWG Observational Relapsed or refractory | VD+Dox or PLD | ⩾VGPR PR | 16 27 | — | 83 16 | 0.02 | — | 90 63 | 0.06 |
| OS | 1 yr | P-value | |||||||
| Pineda-Roman et al.68 Ph 1/2 Relapsed or refractory | VT±D | ⩾MR <MR | 62 20 | — | — | — | — | 73 20 | <0.0001 |
| mPFS | P-value | mOS | P-value | ||||||
| Quach et al.69 EMBT Pooled analysis of two Ph 2 studies Relapsed or refractory | T+IFN or T+celecoxib | ⩾VGPR PR MR or non-response MR non-response | 9 47 48 18 30 | 69 14 4 6.1 3.8 | — | <0.001 PR versus MR or non-response | >70 35 11.7 11 14 | — | <0.001 PR versus MR or nonR |
| mTTP | P-value | mOS | 2 yr | P-value | |||||
| Harousseau et al32 mEBMT Retro of two Ph 3 trial Relapsed or refractory | RD arm | CR/VGPR PR | 114 100 | 27.7 12.0 | <0.001 | NR 44.2 | 59.6 42.0 | 0.021 | |
Abbreviations: BTZ, bortezomib; EFS, event-free survival; IFN, interferon; IMWG, International Myeloma Working Group; mEBMT, modified European Group for Blood and Marrow Transplantation; mo, months; mOS, median overall survival; mPFS, median progression-free survival; mTTP, median time to progression; NR, not reached; nonR, non-response; RD, lenalidomide and dexamethasone; T, thalidomide; VD, bortezomib, dexamethasone; VGPR, very good partial response; yr, years.
a
Conversion to months for studies reporting other time increments.